Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 2/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907366 | 0.83 | UGCG (0.59) | UGCGSCN9ACACNA1HCACNA1GCACNA1I | |
| SCHEMBL29907644 | 0.83 | UGCG (0.68) | UGCG | |
| SCHEMBL29839343 | 0.82 | SCN9A (0.43) | UGCGSCN9ACACNA1HCACNA1GCACNA1C | |
| SCHEMBL22729477 | 0.82 | SCN9A (0.43) | UGCGSCN9ACACNA1HCACNA1GCACNA1C | |
| SCHEMBL24464252 | 0.80 | UGCG (0.66) | UGCGKMT2A | |
| SCHEMBL29907444 | 0.80 | UGCG (0.66) | UGCGKMT2A | |
| SCHEMBL29907413 | 0.79 | UGCG (0.62) | UGCGSCN9ACACNA1HCACNA1GCACNA1C | |
| SCHEMBL29907619 | 0.79 | UGCG (0.72) | UGCGSCN9A | |
| SCHEMBL29907554 | 0.79 | UGCG (0.72) | UGCGMEN1KMT2A | |
| SCHEMBL29907618 | 0.79 | UGCG (0.62) | UGCGGPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885SCN9A 1952/4885CACNA1H 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.